MX373045B - Inhibidores de mdm2 y metodos terapeuticos que utilizan el mismo. - Google Patents
Inhibidores de mdm2 y metodos terapeuticos que utilizan el mismo.Info
- Publication number
- MX373045B MX373045B MX2016013457A MX2016013457A MX373045B MX 373045 B MX373045 B MX 373045B MX 2016013457 A MX2016013457 A MX 2016013457A MX 2016013457 A MX2016013457 A MX 2016013457A MX 373045 B MX373045 B MX 373045B
- Authority
- MX
- Mexico
- Prior art keywords
- same
- mdm2
- therapeutic methods
- mdm2 inhibitors
- inhibitors
- Prior art date
Links
- 239000012819 MDM2-Inhibitor Substances 0.000 title abstract 2
- 238000002560 therapeutic procedure Methods 0.000 title 1
- 102000012199 E3 ubiquitin-protein ligase Mdm2 Human genes 0.000 abstract 3
- 108050002772 E3 ubiquitin-protein ligase Mdm2 Proteins 0.000 abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 230000003993 interaction Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/20—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
- A61N2005/1092—Details
- A61N2005/1098—Enhancing the effect of the particle by an injected agent or implanted device
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Pathology (AREA)
- Radiology & Medical Imaging (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461980747P | 2014-04-17 | 2014-04-17 | |
| PCT/US2015/026098 WO2015161032A1 (en) | 2014-04-17 | 2015-04-16 | Mdm2 inhibitors and therapeutic methods using the same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2016013457A MX2016013457A (es) | 2017-05-04 |
| MX373045B true MX373045B (es) | 2020-05-26 |
Family
ID=54321424
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016013457A MX373045B (es) | 2014-04-17 | 2015-04-16 | Inhibidores de mdm2 y metodos terapeuticos que utilizan el mismo. |
| MX2020003939A MX2020003939A (es) | 2014-04-17 | 2016-10-13 | Inhibidores de mdm2 y metodos terapeuticos que utilizan los mismos. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020003939A MX2020003939A (es) | 2014-04-17 | 2016-10-13 | Inhibidores de mdm2 y metodos terapeuticos que utilizan los mismos. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US9745314B2 (OSRAM) |
| EP (1) | EP3131544B1 (OSRAM) |
| JP (2) | JP6694827B2 (OSRAM) |
| KR (2) | KR102599945B1 (OSRAM) |
| CN (2) | CN111718354A (OSRAM) |
| AU (1) | AU2015247646B2 (OSRAM) |
| CA (1) | CA2945527C (OSRAM) |
| ES (1) | ES2712973T3 (OSRAM) |
| IL (2) | IL248211B (OSRAM) |
| MX (2) | MX373045B (OSRAM) |
| SG (2) | SG10201913742TA (OSRAM) |
| WO (1) | WO2015161032A1 (OSRAM) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0811643D0 (en) | 2008-06-25 | 2008-07-30 | Cancer Rec Tech Ltd | New therapeutic agents |
| JP6694827B2 (ja) * | 2014-04-17 | 2020-05-20 | ザ リージェンツ オブ ザ ユニバーシティー オブ ミシガン | Ｍｄｍ２阻害剤及びそれを使用する治療方法 |
| CN107001385B (zh) | 2014-08-21 | 2020-03-13 | 勃林格殷格翰国际有限公司 | 作为mdm2-p53抑制剂的螺-[3h-吲哚-3，2’-吡咯烷]-2(1h)-酮化合物及其衍生物 |
| US9962380B2 (en) * | 2015-09-23 | 2018-05-08 | Wisconsin Alumni Research Foundation | Methods for treating cognitive deficits associated with fragile X syndrome |
| GB201517216D0 (en) | 2015-09-29 | 2015-11-11 | Cancer Res Technology Ltd And Astex Therapeutics Ltd | Pharmaceutical compounds |
| GB201517217D0 (en) | 2015-09-29 | 2015-11-11 | Astex Therapeutics Ltd And Cancer Res Technology Ltd | Pharmaceutical compounds |
| CN119569740A (zh) | 2015-10-09 | 2025-03-07 | 勃林格殷格翰国际有限公司 | 作为mdm2-p53抑制剂的化合物及其衍生物 |
| EP3440066B1 (en) * | 2016-04-06 | 2022-11-30 | The Regents of The University of Michigan | Mdm2 protein degraders |
| CN118436801A (zh) | 2016-05-20 | 2024-08-06 | 豪夫迈·罗氏有限公司 | Protac抗体缀合物及其使用方法 |
| GB201704966D0 (en) | 2017-03-28 | 2017-05-10 | Astex Therapeutics Ltd | Pharmaceutical compounds |
| GB201704965D0 (en) | 2017-03-28 | 2017-05-10 | Astex Therapeutics Ltd | Pharmaceutical compounds |
| SG11202006262TA (en) * | 2017-12-29 | 2020-07-29 | Gan & Lee Pharmaceuticals | Compound capable of being used as tumor inhibitor, preparation method therefor, and application thereof |
| EP3511334A1 (en) * | 2018-01-16 | 2019-07-17 | Adamed sp. z o.o. | 1,2,3',5'-tetrahydro-2'h-spiro[indole-3,1'-pyrrolo[3,4-c]pyrrole]-2,3'-dione compounds as therapeutic agents activating tp53 |
| KR102039696B1 (ko) | 2018-04-23 | 2019-11-04 | 충남대학교산학협력단 | 세포내 결핵균 제어를 위한 p53 발현 조절 가능한 조성물 (K279-1558) 또는 방법 |
| CN110776507B (zh) | 2018-07-31 | 2020-12-18 | 苏州亚盛药业有限公司 | Bcl-2抑制剂与化疗药的组合产品及其在预防和/或治疗疾病中的用途 |
| CN110772521A (zh) | 2018-07-31 | 2020-02-11 | 苏州亚盛药业有限公司 | Bcl-2抑制剂或Bcl-2/Bcl-xL抑制剂与BTK抑制剂的组合产品及其用途 |
| JP7058345B2 (ja) * | 2018-07-31 | 2022-04-21 | アセンテージ ファーマ（スーチョウ）カンパニー，リミティド | Ｂｃｌ－２阻害剤及びＭＤＭ２阻害剤の組合せ製品並びに疾患の予防及び／又治療におけるその使用 |
| TWI726362B (zh) | 2018-07-31 | 2021-05-01 | 大陸商蘇州亞盛藥業有限公司 | Bcl-2抑制劑與利妥昔單抗和/或苯達莫司汀或Bcl-2抑制劑與CHOP聯合用藥的協同抗腫瘤作用 |
| US12268665B2 (en) | 2018-08-08 | 2025-04-08 | Ascentage Pharma (Suzhou) Co., Ltd | Combination of immunotherapies with MDM2 inhibitors |
| TWI750539B (zh) * | 2018-11-23 | 2021-12-21 | 大陸商蘇州亞盛藥業有限公司 | 新穎藥物組成物及其用途 |
| AU2019399772B2 (en) * | 2018-12-14 | 2021-11-04 | Ascentage Pharma (Suzhou) Co., Ltd. | A compound for treating osteoarthritis |
| WO2020169073A1 (en) * | 2019-02-24 | 2020-08-27 | Ascentage Pharma (Suzhou) Co., Ltd. | Treatment methods and biomarkers for mdm2 inhibitors |
| EP3814358B1 (en) * | 2019-07-11 | 2025-09-03 | Ascentage Pharma (Suzhou) Co., Ltd. | Method for preparing 2-indolinospirone compounds and intermediates thereof |
| TW202116301A (zh) * | 2019-07-19 | 2021-05-01 | 大陸商蘇州亞盛藥業有限公司 | 藥物組合及其用途 |
| WO2021018032A1 (en) * | 2019-07-26 | 2021-02-04 | Ascentage Pharma (Suzhou) Co., Ltd. | Pharmaceutical composition of mdm2 inhibitor and use thereof for preventing and/or treating disease |
| CN112852959A (zh) * | 2019-11-27 | 2021-05-28 | 苏州亚盛药业有限公司 | 用于预测靶向细胞凋亡途径的化合物的抗癌功效的方法和组合物 |
| US11850239B2 (en) | 2019-12-19 | 2023-12-26 | Ascentage Pharma (Suzhou) Co., Ltd. | MDM2 inhibitor and a platinum compound for cancer treatment |
| GB201919219D0 (en) | 2019-12-23 | 2020-02-05 | Otsuka Pharma Co Ltd | Cancer biomarkers |
| TWI777380B (zh) * | 2020-01-23 | 2022-09-11 | 大陸商蘇州亞盛藥業有限公司 | 2-吲哚啉螺環酮類化合物之結晶形式 |
| WO2021175192A1 (en) * | 2020-03-02 | 2021-09-10 | Ascentage Pharma (Suzhou) Co., Ltd. | Treatment methods and biomarkers for mdm2 inhibitors |
| EP4121043A4 (en) * | 2020-03-19 | 2024-07-24 | Kymera Therapeutics, Inc. | Mdm2 degraders and uses thereof |
| US20230149356A1 (en) * | 2020-04-14 | 2023-05-18 | Ascentage Pharma (Suzhou) Co., Ltd. | Novel medical use of mdm2 inhibitors |
| WO2021254277A1 (en) * | 2020-06-15 | 2021-12-23 | Ascentage Pharma (Suzhou) Co., Ltd. | Microsuspension of an mdm2 inhibitor and therapeutic applications thereof |
| CA3181715A1 (en) | 2020-08-27 | 2022-03-03 | Otsuka Pharmaceutical Co., Ltd. | Biomarkers for cancer therapy using mdm2 antagonists |
| CN112022812B (zh) * | 2020-11-03 | 2021-01-29 | 上海亚盛医药科技有限公司 | 一种包含杂环类化合物的组合物、其制备方法和应用 |
| WO2022170108A1 (en) * | 2021-02-04 | 2022-08-11 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles and uses thereof in prevention of radiation injury |
| CN116917009A (zh) | 2021-02-19 | 2023-10-20 | 美国迈胜医疗系统有限公司 | 用于粒子治疗系统的机架 |
| GB202103080D0 (en) | 2021-03-04 | 2021-04-21 | Otsuka Pharma Co Ltd | Cancer biomarkers |
| WO2023011488A1 (zh) | 2021-08-02 | 2023-02-09 | 苏州亚盛药业有限公司 | 一种药物组合及其用途 |
| WO2023056069A1 (en) | 2021-09-30 | 2023-04-06 | Angiex, Inc. | Degrader-antibody conjugates and methods of using same |
| WO2023134707A1 (en) * | 2022-01-11 | 2023-07-20 | Ascentage Pharma (Suzhou) Co., Ltd. | Methods for treating aml-mrc and mds |
| WO2024240858A1 (en) | 2023-05-23 | 2024-11-28 | Valerio Therapeutics | Protac molecules directed against dna damage repair system and uses thereof |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3989816A (en) | 1975-06-19 | 1976-11-02 | Nelson Research & Development Company | Vehicle composition containing 1-substituted azacycloheptan-2-ones |
| US4444762A (en) | 1980-04-04 | 1984-04-24 | Nelson Research & Development Company | Vehicle composition containing 1-substituted azacyclopentan-2-ones |
| US6605712B1 (en) | 1990-12-20 | 2003-08-12 | Arch Development Corporation | Gene transcription and ionizing radiation: methods and compositions |
| US7759383B2 (en) | 2005-02-22 | 2010-07-20 | The Regents Of The University Of Michigan | Small molecule inhibitors of MDM2 and the uses thereof |
| CN101316823B (zh) | 2005-12-01 | 2013-05-22 | 霍夫曼-拉罗奇有限公司 | 用作抗癌剂的作为p53和MDM2蛋白之间相互作用的抑制剂的2,4,5-三苯基咪唑啉衍生物 |
| KR101052706B1 (ko) * | 2006-03-13 | 2011-08-01 | 에프. 호프만-라 로슈 아게 | 스피로인돌리논 유도체 |
| CN101400680B (zh) * | 2006-03-13 | 2012-04-25 | 霍夫曼-拉罗奇有限公司 | 螺吲哚满酮衍生物 |
| CN101528223B (zh) * | 2006-08-30 | 2013-05-01 | 密执安州立大学董事会 | Mdm2的新型小分子抑制剂和其用途 |
| US7737174B2 (en) | 2006-08-30 | 2010-06-15 | The Regents Of The University Of Michigan | Indole inhibitors of MDM2 and the uses thereof |
| US8222288B2 (en) | 2006-08-30 | 2012-07-17 | The Regents Of The University Of Michigan | Small molecule inhibitors of MDM2 and the uses thereof |
| US20080206794A1 (en) | 2006-09-15 | 2008-08-28 | Renovar Incorporated | Systems And Methods For Characterizing Contrast Induced-Nephropathy |
| US20080188506A1 (en) * | 2007-02-07 | 2008-08-07 | Qingjie Ding | Spiroindolinone derivatives |
| US8354444B2 (en) | 2008-09-18 | 2013-01-15 | Hoffmann-La Roche Inc. | Substituted pyrrolidine-2-carboxamides |
| RU2506257C2 (ru) | 2008-09-18 | 2014-02-10 | Ф.Хоффманн-Ля Рош Аг | Замещенные пирролидин-2-карбоксамиды |
| US8076482B2 (en) * | 2009-04-23 | 2011-12-13 | Hoffmann-La Roche Inc. | 3,3′-spiroindolinone derivatives |
| JP2013510860A (ja) * | 2009-11-12 | 2013-03-28 | ザ、リージェンツ、オブ、ザ、ユニバーシティ、オブ、ミシガン | スピロ−オキシインドールｍｄｍ２アンタゴニスト |
| US8088815B2 (en) | 2009-12-02 | 2012-01-03 | Hoffman-La Roche Inc. | Spiroindolinone pyrrolidines |
| KR20130050938A (ko) * | 2010-04-09 | 2013-05-16 | 더 리젠츠 오브 더 유니버시티 오브 미시건 | 질환 치료시 사용하기 위한 ｍｄｍ2 억제제에 대한 바이오마커 |
| US8217044B2 (en) * | 2010-04-28 | 2012-07-10 | Hoffmann-La Roche Inc. | Spiroindolinone pyrrolidines |
| JO2998B1 (ar) | 2010-06-04 | 2016-09-05 | Amgen Inc | مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان |
| US20120046306A1 (en) | 2010-08-18 | 2012-02-23 | David Joseph Bartkovitz | Substituted Heteroaryl Spiropyrrolidine MDM2 Antagonists |
| UY33725A (es) | 2010-11-12 | 2012-06-29 | Sanofi Sa | Antagonistas de mdm2 de espiro-oxindol |
| RU2612534C2 (ru) * | 2011-03-10 | 2017-03-09 | Дайити Санкио Компани, Лимитед | Диспиропирролидиновые производные |
| MX346375B (es) * | 2011-05-11 | 2017-03-16 | Univ Michigan Regents | Antagonistas de espiro-oxindol de mdm2. |
| MX352672B (es) | 2011-09-27 | 2017-12-04 | Amgen Inc | Compuestos heterocíclicos como inhibidores de mdm2 para el tratamiento del cáncer. |
| CN105555789B (zh) * | 2013-09-04 | 2018-08-10 | 第一三共株式会社 | 螺氧基吲哚衍生物的制备方法 |
| JP6694827B2 (ja) * | 2014-04-17 | 2020-05-20 | ザ リージェンツ オブ ザ ユニバーシティー オブ ミシガン | Ｍｄｍ２阻害剤及びそれを使用する治療方法 |
-
2015
- 2015-04-16 JP JP2016562752A patent/JP6694827B2/ja active Active
- 2015-04-16 SG SG10201913742TA patent/SG10201913742TA/en unknown
- 2015-04-16 KR KR1020227012871A patent/KR102599945B1/ko active Active
- 2015-04-16 ES ES15779988T patent/ES2712973T3/es active Active
- 2015-04-16 WO PCT/US2015/026098 patent/WO2015161032A1/en not_active Ceased
- 2015-04-16 EP EP15779988.3A patent/EP3131544B1/en active Active
- 2015-04-16 SG SG11201608667SA patent/SG11201608667SA/en unknown
- 2015-04-16 KR KR1020167031180A patent/KR102389552B1/ko active Active
- 2015-04-16 MX MX2016013457A patent/MX373045B/es active IP Right Grant
- 2015-04-16 CN CN202010081463.0A patent/CN111718354A/zh active Pending
- 2015-04-16 AU AU2015247646A patent/AU2015247646B2/en active Active
- 2015-04-16 CN CN201580032547.2A patent/CN106794171B/zh active Active
- 2015-04-16 CA CA2945527A patent/CA2945527C/en active Active
- 2015-04-16 US US14/688,553 patent/US9745314B2/en active Active
-
2016
- 2016-10-06 IL IL24821116A patent/IL248211B/en active IP Right Grant
- 2016-10-13 MX MX2020003939A patent/MX2020003939A/es unknown
-
2019
- 2019-09-19 IL IL269462A patent/IL269462B/en active IP Right Grant
-
2020
- 2020-02-28 JP JP2020033622A patent/JP6909323B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| KR20160136450A (ko) | 2016-11-29 |
| KR20220054697A (ko) | 2022-05-03 |
| SG11201608667SA (en) | 2016-11-29 |
| MX2016013457A (es) | 2017-05-04 |
| CN106794171B (zh) | 2020-03-24 |
| AU2015247646A1 (en) | 2016-10-27 |
| JP2020100662A (ja) | 2020-07-02 |
| KR102389552B1 (ko) | 2022-04-22 |
| US20150299211A1 (en) | 2015-10-22 |
| IL248211B (en) | 2019-10-31 |
| US9745314B2 (en) | 2017-08-29 |
| CN111718354A (zh) | 2020-09-29 |
| IL269462B (en) | 2021-05-31 |
| AU2015247646B2 (en) | 2019-06-06 |
| JP2017511360A (ja) | 2017-04-20 |
| CN106794171A (zh) | 2017-05-31 |
| SG10201913742TA (en) | 2020-03-30 |
| CA2945527A1 (en) | 2015-10-22 |
| EP3131544B1 (en) | 2018-12-12 |
| WO2015161032A1 (en) | 2015-10-22 |
| MX2020003939A (es) | 2020-08-13 |
| JP6694827B2 (ja) | 2020-05-20 |
| EP3131544A1 (en) | 2017-02-22 |
| IL269462A (en) | 2019-11-28 |
| CA2945527C (en) | 2022-05-17 |
| KR102599945B1 (ko) | 2023-11-09 |
| JP6909323B2 (ja) | 2021-07-28 |
| IL248211A0 (en) | 2016-11-30 |
| ES2712973T3 (es) | 2019-05-17 |
| EP3131544A4 (en) | 2017-08-30 |
| NZ724963A (en) | 2021-10-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX373045B (es) | Inhibidores de mdm2 y metodos terapeuticos que utilizan el mismo. | |
| CY1124131T1 (el) | Συζευγματα αντι-ρτκ7 αντισωματος-φαρμακου | |
| CY1124215T1 (el) | Μκ2 αναστολεις και χρησεις αυτων | |
| IL269150A (en) | Compositions and methods for treating cancer | |
| MX378273B (es) | Compuestos activos hacia bromodominios. | |
| NZ731467A (en) | Anti-tim3 antibodies and methods of use | |
| JOP20190194A1 (ar) | مركبات نيوكليوتيدات ثنائية حلقية لعلاج السرطان | |
| IL268814A (en) | Compositions and methods for treatment of cancer | |
| CL2016002027A1 (es) | Ciclopropilamina como inhibidor de la lsd1 | |
| PH12017500877B1 (en) | ANTI-CD79b ANTIBODIES AND METHODS OF USE | |
| MX2018005315A (es) | Composiciones y metodos para el tratamiento del cancer. | |
| MA40579A (fr) | Anticorps anti-cll-1 et immunoconjugués | |
| MX2019001471A (es) | Anticuerpos anti-siglec-7 para el tratamiento del cancer. | |
| EA201691594A1 (ru) | Циклопропиламины в качестве ингибиторов lsd1 | |
| EA201790170A1 (ru) | Терапевтические соединения-ингибиторы | |
| MY176855A (en) | Anti-jagged1 antibodies and methods of use | |
| MX2016015162A (es) | Anticuerpos anti - gpc3 e inmunoconjugados. | |
| CL2016003074A1 (es) | Compuestos derivados de 2-oxi-2-fenil-n-5-pirrolidin-3-ilamino-1,3,4-tiadiazol-2-ilacetamida, inhibidores gls1 composición farmacéutica y su uso para tratar el cáncer. | |
| IL269157A (en) | Compositions and methods for treating cancer | |
| MX2016009590A (es) | Composiciones de apilimod y métodos para usar las mismas. | |
| EA201791454A1 (ru) | Лекарственные формы для трансдермального введения | |
| EA201790312A1 (ru) | Комбинации лекарственных средств для лечения множественной миеломы | |
| BR112017000730B8 (pt) | Derivados de pirrolidinona como inibidores de metap-2, e medicamentos | |
| LT3534885T (lt) | Farneziltransferazės inhibitoriai, skirti naudoti vėžio gydymui | |
| JO3541B1 (ar) | علاجات طبية قائمة على اناموريلين |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |